These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37452461)

  • 1. Impaired aldehyde detoxification exacerbates motor deficits in an alpha-synuclein mouse model of Parkinson's disease.
    Martinez PA; Martinez VE; Rani S; Murrell M; Javors M; Gelfond J; Doorn JA; Fernandez E; Strong R
    Brain Behav; 2023 Sep; 13(9):e3150. PubMed ID: 37452461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    Lima VA; do Nascimento LA; Eliezer D; Follmer C
    ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
    J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
    Wey MC; Fernandez E; Martinez PA; Sullivan P; Goldstein DS; Strong R
    PLoS One; 2012; 7(2):e31522. PubMed ID: 22384032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.
    Liu G; Yu J; Ding J; Xie C; Sun L; Rudenko I; Zheng W; Sastry N; Luo J; Rudow G; Troncoso JC; Cai H
    J Clin Invest; 2014 Jul; 124(7):3032-46. PubMed ID: 24865427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
    Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
    J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin.
    Plotegher N; Bubacco L
    Ageing Res Rev; 2016 Mar; 26():62-71. PubMed ID: 26690800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
    Kumar VB; Hsu FF; Lakshmi VM; Gillespie KN; Burke WJ
    Eur J Pharmacol; 2019 Feb; 845():65-73. PubMed ID: 30579934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
    Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS
    J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
    Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
    J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
    Goldstein DS
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired dopamine metabolism in Parkinson's disease pathogenesis.
    Masato A; Plotegher N; Boassa D; Bubacco L
    Mol Neurodegener; 2019 Aug; 14(1):35. PubMed ID: 31488222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of large oligomers of DOPAL-modified α-synuclein is modulated by the oxidation of methionine residues located at C-terminal domain.
    Coelho-Cerqueira E; de Araújo Correia Campos C; Follmer C
    Biochem Biophys Res Commun; 2019 Feb; 509(2):367-372. PubMed ID: 30591215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.
    Jinsmaa Y; Cooney A; Sullivan P; Sharabi Y; Goldstein DS
    Neurosci Lett; 2015 Mar; 590():134-7. PubMed ID: 25637699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.
    Sarafian TA; Yacoub A; Kunz A; Aranki B; Serobyan G; Cohn W; Whitelegge JP; Watson JB
    J Neurosci Res; 2019 Dec; 97(12):1689-1705. PubMed ID: 31420910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the role of methionine residues on the oligomerization and neurotoxic properties of DOPAL-modified α-synuclein.
    Carmo-Gonçalves P; do Nascimento LA; Cortines JR; Eliezer D; Romão L; Follmer C
    Biochem Biophys Res Commun; 2018 Oct; 505(1):295-301. PubMed ID: 30249394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo electrophysiology of nigral and thalamic neurons in alpha-synuclein-overexpressing mice highlights differences from toxin-based models of parkinsonism.
    Lobb CJ; Zaheer AK; Smith Y; Jaeger D
    J Neurophysiol; 2013 Dec; 110(12):2792-805. PubMed ID: 24068758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice.
    Ninkina N; Tarasova TV; Chaprov KD; Roman AY; Kukharsky MS; Kolik LG; Ovchinnikov R; Ustyugov AA; Durnev AD; Buchman VL
    Neurobiol Aging; 2020 Jul; 91():76-87. PubMed ID: 32224067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.